Stephen Brown
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Stephen Brown has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Vaidehi Jobanputra
New York Genome Center
2 shared publications - Andrey V Krylatov
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
1 shared publication Antonio Sobrino
New York Presbyterian Hospital, New York, NY
1 shared publicationB. Waters
Department of Pathology; University of Vermont; Burlington VT USA
1 shared publicationCecilia Esteves
Department of Pathology, Columbia University, New York, NY
1 shared publicationCheung Wong
The authors declare no conflict of interest
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Pathology
- Vol. 2026 (1)
Case Report: A Previously Healthy Young Woman With Lethal, Unremitting Metabolic Acidosis: Could a Novel Variant in ALAS2 Be the Culprit?
Background: Heme synthesis is critical for several biological processes, including mitochondrial energy production and oxygen delivery via hemoglobin. The initial and rate‐limiting step in heme synthesis is the conjugation of glycine with succinyl‐CoA to form 5‐aminolevulinic acid (ALA), which is catalyzed by two closely related enzymes that are coded by highly homologous genes, known as ALAS1 and ALAS2 . Loss‐of‐function variants in ALAS2 result in sideroblastic anemia, whereas gain‐of‐function variants result in porphyria. We present a case of a woman who died with severe metabolic acidosis and was found to have a rare variant in ALAS2 . We propose the hypothesis that the ALAS2 variant, in conjunction with other factors, was responsible for her demise. Case Report: A previously healthy 34‐year‐old woman presented to the emergency department of her local hospital complaining of severe fatigue. Her arterial pH was 6.95. No cause for her acidosis could be identified, and she expired from unremitting acidosis. The autopsy was notable for an enlarged liver. Whole exome sequencing identified a rare, paternally inherited variant in ALAS2 . This prompted a re‐evaluation of the autopsy and the development of a novel hypothesis to explain her acidosis. We propose that the ALAS2 variant identified in this family, NM_000032.5( ALAS2 )c.1273C>T(p.Pro425Ser), is a conditional allele that can contribute to mitochondrial dysfunction under unusual conditions. Discussion: We hypothesize that the P425S variant identified in ALAS2 leads to dysfunction of the homeostatic down‐regulation of ALAS2 in times of cofactor deficiency. This case illustrates that DNA sequencing as a part of the autopsy procedure will, as it becomes more routine, lead to the identification of sequence variants that may or may not be clinically relevant. The pursuit of hypotheses, prompted by genetic data, has the potential to identify novel pathogenic mechanisms.
- 1 January 2026
- Published by Wiley in Case Reports in Pathology
- Vol. 2026 (1)
Open AccessCase Report: A Previously Healthy Young Woman With Lethal, Unremitting Metabolic Acidosis: Could a Novel Variant in ALAS2 Be the Culprit?
Background: Heme synthesis is critical for several biological processes, including mitochondrial energy production and oxygen delivery via hemoglobin. The initial and rate‐limiting step in heme synthesis is the conjugation of glycine with succinyl‐CoA to form 5‐aminolevulinic acid (ALA), which is catalyzed by two closely related enzymes that are coded by highly homologous genes, known as ALAS1 and ALAS2 . Loss‐of‐function variants in ALAS2 result in sideroblastic anemia, whereas gain‐of‐function variants result in porphyria. We present a case of a woman who died with severe metabolic acidosis and was found to have a rare variant in ALAS2 . We propose the hypothesis that the ALAS2 variant, in conjunction with other factors, was responsible for her demise. Case Report: A previously healthy 34‐year‐old woman presented to the emergency department of her local hospital complaining of severe fatigue. Her arterial pH was 6.95. No cause for her acidosis could be identified, and she expired from unremitting acidosis. The autopsy was notable for an enlarged liver. Whole exome sequencing identified a rare, paternally inherited variant in ALAS2 . This prompted a re‐evaluation of the autopsy and the development of a novel hypothesis to explain her acidosis. We propose that the ALAS2 variant identified in this family, NM_000032.5( ALAS2 )c.1273C>T(p.Pro425Ser), is a conditional allele that can contribute to mitochondrial dysfunction under unusual conditions. Discussion: We hypothesize that the P425S variant identified in ALAS2 leads to dysfunction of the homeostatic down‐regulation of ALAS2 in times of cofactor deficiency. This case illustrates that DNA sequencing as a part of the autopsy procedure will, as it becomes more routine, lead to the identification of sequence variants that may or may not be clinically relevant. The pursuit of hypotheses, prompted by genetic data, has the potential to identify novel pathogenic mechanisms.
- Open Access
- 5 December 2022
- Published by Wiley in Clinical Case Reports
- Vol. 10 (12) , e6706
Exome sequencing identifies a cryptic chromosome translocation in a family decades after clinical diagnosis of Cornelia de Lange: Case report
Clinical genetic evaluations are defined by the knowledge and technology available at the time they occur. In the modern era, microarray and exome sequencing are first line tests for clinical geneticists; however, beginning in the late 1970s and continuing until the turn of the past century, a standard genetic evaluation consisted, in many cases, of an examination by a dysmorphologist as well as a conventional karyotype. In general, once a genetic diagnosis is established, it does not get revisited as more advanced methods become available. Clearly, there will be instances in which new technology can modify or change a prior diagnosis. We present a family in which the recent birth of a baby resulted in the establishment of a cytogenetic diagnosis of a different family member whose initial evaluation and clinical diagnosis had occurred three decades earlier. The new genomic findings have profound implications for other family members, and in addition provided the family with a sense of closure.
- 5 December 2022
- Published by Wiley in Clinical Case Reports
- Vol. 10 (12) , e6706
Open AccessExome sequencing identifies a cryptic chromosome translocation in a family decades after clinical diagnosis of Cornelia de Lange: Case report
Clinical genetic evaluations are defined by the knowledge and technology available at the time they occur. In the modern era, microarray and exome sequencing are first line tests for clinical geneticists; however, beginning in the late 1970s and continuing until the turn of the past century, a standard genetic evaluation consisted, in many cases, of an examination by a dysmorphologist as well as a conventional karyotype. In general, once a genetic diagnosis is established, it does not get revisited as more advanced methods become available. Clearly, there will be instances in which new technology can modify or change a prior diagnosis. We present a family in which the recent birth of a baby resulted in the establishment of a cytogenetic diagnosis of a different family member whose initial evaluation and clinical diagnosis had occurred three decades earlier. The new genomic findings have profound implications for other family members, and in addition provided the family with a sense of closure.
- 1 March 2020
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 35 (3) , 485-487
Identity-by-state analysis: a new method for PGT-M
- 1 March 2020
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 35 (3) , 485-487
Identity-by-state analysis: a new method for PGT-M
- 27 January 2017
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 41 (2) , 265-274
Breast Durometer (Mammometer): A Novel Device for Measuring Soft-Tissue Firmness and Its Application in Cosmetic Breast Surgery
The measurement of soft-tissue firmness has many potential applications in medical practice. This study reports a user-friendly, novel device that is capable of measuring changes in soft-tissue firmness in a reproducible manner. The study reports the development of the equipment and how it has been applied to breast implant surgery. The device was tested for both intra- and inter-observer variability on an in vitro model, using a breast implant. Once reproducibility was confirmed, breast firmness was measured on a series of patients who underwent sub-fascial breast augmentation (n = 50) to examine how it varied post-operatively. Firmness in the upper half of the breast increased to a maximum level two weeks post-surgery (0.44–0.61 Pa), reducing to pre-operative levels by 6 weeks (0.37–0.54 Pa). There was no further significant change at 12 weeks. Firmness in the nipple areolar complex (NAC) and at the lower outer quadrant (LOQ) followed a similar pattern, but remained firmer at 12 weeks. We interpret these patterns as implying that measurements taken at the upper half of the breast are indicative of post-operative oedema, whereas those at the NAC and LOQ represent changes in firmness produced by the breast implant composite. We consider the potential for this novel device in the measurement of soft-tissue firmness in aesthetic breast surgery and would encourage other researchers to explore novel applications. Level of Evidence III This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
- 27 January 2017
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 41 (2) , 265-274
Breast Durometer (Mammometer): A Novel Device for Measuring Soft-Tissue Firmness and Its Application in Cosmetic Breast Surgery
The measurement of soft-tissue firmness has many potential applications in medical practice. This study reports a user-friendly, novel device that is capable of measuring changes in soft-tissue firmness in a reproducible manner. The study reports the development of the equipment and how it has been applied to breast implant surgery. The device was tested for both intra- and inter-observer variability on an in vitro model, using a breast implant. Once reproducibility was confirmed, breast firmness was measured on a series of patients who underwent sub-fascial breast augmentation (n = 50) to examine how it varied post-operatively. Firmness in the upper half of the breast increased to a maximum level two weeks post-surgery (0.44–0.61 Pa), reducing to pre-operative levels by 6 weeks (0.37–0.54 Pa). There was no further significant change at 12 weeks. Firmness in the nipple areolar complex (NAC) and at the lower outer quadrant (LOQ) followed a similar pattern, but remained firmer at 12 weeks. We interpret these patterns as implying that measurements taken at the upper half of the breast are indicative of post-operative oedema, whereas those at the NAC and LOQ represent changes in firmness produced by the breast implant composite. We consider the potential for this novel device in the measurement of soft-tissue firmness in aesthetic breast surgery and would encourage other researchers to explore novel applications. Level of Evidence III This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
- 27 October 2014
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 44 (6) , 719-721
First-trimester diagnosis of Meckel-Gruber syndrome by fetal ultrasound with molecular identification of CC2D2A mutations by next-generation sequencing
We describe a first‐trimester ultrasound examination in which the finding of fetal encephalocele and the cystic appearance of the kidneys raised suspicion of Meckel–Gruber syndrome (MKS). On the basis of sonographic findings, the patient elected termination of pregnancy, and post‐termination studies using next‐generation sequencing of a gene panel revealed two mutations (one previously described and the other novel) in the gene CC2D2A. Mutations in CC2D2A are known to cause MKS and Joubert syndrome, thus providing molecular confirmation of the clinical suspicion of MKS and opening the possibility for future prenatal diagnosis. This case highlights the ability to detect important anomalies in the first trimester using ultrasound, even in low‐risk situations. It also demonstrates the growing role of new sequencing technologies in fetal testing. Copyright © 2014 ISUOG. Published by John Wiley & Sons Ltd.
- 27 October 2014
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 44 (6) , 719-721
First-trimester diagnosis of Meckel-Gruber syndrome by fetal ultrasound with molecular identification of CC2D2A mutations by next-generation sequencing
We describe a first‐trimester ultrasound examination in which the finding of fetal encephalocele and the cystic appearance of the kidneys raised suspicion of Meckel–Gruber syndrome (MKS). On the basis of sonographic findings, the patient elected termination of pregnancy, and post‐termination studies using next‐generation sequencing of a gene panel revealed two mutations (one previously described and the other novel) in the gene CC2D2A. Mutations in CC2D2A are known to cause MKS and Joubert syndrome, thus providing molecular confirmation of the clinical suspicion of MKS and opening the possibility for future prenatal diagnosis. This case highlights the ability to detect important anomalies in the first trimester using ultrasound, even in low‐risk situations. It also demonstrates the growing role of new sequencing technologies in fetal testing. Copyright © 2014 ISUOG. Published by John Wiley & Sons Ltd.
- Open Access
- 6 January 2014
- Published by Wiley in Academic Emergency Medicine
- Vol. 21 (1) , 31-39
Activation of Peripheral Delta Opioid Receptors Increases Cardiac Tolerance to Arrhythmogenic Effect of Ischemia/Reperfusion
Objectives: The objective of this study was to investigate the role of peripheral μ, δ1, δ2, and nociceptin opioid receptors agonists in the regulation of cardiac tolerance to the arrhythmogenic effect of ischemia/reperfusion in rats.Methods: Anesthetized open‐chest male Wistar rats were subjected to either 45 minutes of left coronary artery occlusion (phase 1a 10 minutes and phase 2b 35 minutes) and 2 hours of reperfusion in Experiment 1 or 10 minutes of ischemia and 10 minutes of reperfusion in Experiment 2. In Experiment 1, saline or vehicle controls and the mu‐specific opioids dermorphin‐H (Derm‐H) and ([d‐Ala2,N‐Me‐Phe4, Gly‐ol5] enkephalin (DAMAGO); the delta‐1–specific opioidd‐Pen2,5enkephalin (DPDPE); nociceptin; and the delta‐2–specific opioids deltorphin‐II(Delt‐II), Delt‐Dvariant (Delt‐Dvar), and deltorphin‐E (Delt‐E) were infused 15 minutes prior to ischemia. In Experiment 2,DPDPE, Delt‐D, Delt‐Dvar, and Delt‐E were infused at 15 minutes prior to ischemia. The universal opioid receptor antagonist naltrexone, the peripherally acting antagonist naloxone methiodide, the selective δ1antagonist 7‐benzylidene naltrexone maleate, and the specific δ2antagonist naltriben mesylate were infused 25 minutes prior to ischemia.Results: In Experiment 1, pretreatment with the μ opioids Derm‐H andDAMGO,DPDPE, and nociceptin at all doses tested did not reduce the incidence of ischemia‐induced arrhythmias compared to controls during 45 minutes of ischemia. The δ2opioids Delt‐II(0.12 mg/kg), Delt‐Dvar (0.3 mg/kg), and Delt‐E (0.18 mg/kg) all demonstrated significant antiarrhythmic effects at the 150 nmol/kg dose compared to saline or vehicle controls. Nine of 19 animals treated with Delt‐IIwere tolerant without ventricular arrhythmias to the arrhythmogenic effect of ischemia during the first 10 minutes of ischemia (phase 1a) and 11 of 19 were without ventricular arrhythmias during the following 35 minutes of ischemia (phase 1b). Delt‐IIalso decreased the incidence of premature ventricular contractions and ventricular tachycardia by almost half during phase 1a. Delt‐IIdid not affect the incidence of ventricular fibrillation (VF). Pretreatment with Delt‐Dvar and Delt‐E completely blocked the incidence ofVFin phase 1b. Delt‐E also decreased premature ventricular contractions by 50%, and the incidence of ventricular tachycardia decreased over twofold in phase 1b of ischemia. There was no enhanced tolerance by any of the delta‐2 opioids to the arrhythmogenic effect of reperfusion after long‐term ischemia. In Experiment 2, after 10 minutes of ischemia and 10 minutes of reperfusion, Delt‐II(0.12 mg/kg) reduced the incidence of premature ventricular contractions and ventricular tachycardia compared to controls, and completely blocked the incidence ofVFfollowing 10 minutes of reperfusion. Delt‐Dvar and Delt‐E were without effect, as wasDPDPEfollowing 10 minutes of reperfusion. The antiarrhythmic effect of Delt‐IIduring 10 minutes of ischemia and 10 minutes of reperfusion was completely blocked by the peripherally acting opioid receptor inhibitor naloxone methiodide and the selective delta‐2 opioid receptor inhibitor naltriben mesylate, but not by the selective delta‐1 inhibitor 7‐benzylidene naltrexone maleate. The antagonists alone had no effect on arrhythmogenesis.Conclusions: Peripheral delta‐2 opioid receptor activation by Delt‐II, Delt‐Dvar, and Delt‐E enhanced cardiac tolerance to the arrhythmogenic effects of ischemia.
- 6 January 2014
- Published by Wiley in Academic Emergency Medicine
- Vol. 21 (1) , 31-39
Open AccessActivation of Peripheral Delta Opioid Receptors Increases Cardiac Tolerance to Arrhythmogenic Effect of Ischemia/Reperfusion
Objectives: The objective of this study was to investigate the role of peripheral μ, δ1, δ2, and nociceptin opioid receptors agonists in the regulation of cardiac tolerance to the arrhythmogenic effect of ischemia/reperfusion in rats.Methods: Anesthetized open‐chest male Wistar rats were subjected to either 45 minutes of left coronary artery occlusion (phase 1a 10 minutes and phase 2b 35 minutes) and 2 hours of reperfusion in Experiment 1 or 10 minutes of ischemia and 10 minutes of reperfusion in Experiment 2. In Experiment 1, saline or vehicle controls and the mu‐specific opioids dermorphin‐H (Derm‐H) and ([d‐Ala2,N‐Me‐Phe4, Gly‐ol5] enkephalin (DAMAGO); the delta‐1–specific opioidd‐Pen2,5enkephalin (DPDPE); nociceptin; and the delta‐2–specific opioids deltorphin‐II(Delt‐II), Delt‐Dvariant (Delt‐Dvar), and deltorphin‐E (Delt‐E) were infused 15 minutes prior to ischemia. In Experiment 2,DPDPE, Delt‐D, Delt‐Dvar, and Delt‐E were infused at 15 minutes prior to ischemia. The universal opioid receptor antagonist naltrexone, the peripherally acting antagonist naloxone methiodide, the selective δ1antagonist 7‐benzylidene naltrexone maleate, and the specific δ2antagonist naltriben mesylate were infused 25 minutes prior to ischemia.Results: In Experiment 1, pretreatment with the μ opioids Derm‐H andDAMGO,DPDPE, and nociceptin at all doses tested did not reduce the incidence of ischemia‐induced arrhythmias compared to controls during 45 minutes of ischemia. The δ2opioids Delt‐II(0.12 mg/kg), Delt‐Dvar (0.3 mg/kg), and Delt‐E (0.18 mg/kg) all demonstrated significant antiarrhythmic effects at the 150 nmol/kg dose compared to saline or vehicle controls. Nine of 19 animals treated with Delt‐IIwere tolerant without ventricular arrhythmias to the arrhythmogenic effect of ischemia during the first 10 minutes of ischemia (phase 1a) and 11 of 19 were without ventricular arrhythmias during the following 35 minutes of ischemia (phase 1b). Delt‐IIalso decreased the incidence of premature ventricular contractions and ventricular tachycardia by almost half during phase 1a. Delt‐IIdid not affect the incidence of ventricular fibrillation (VF). Pretreatment with Delt‐Dvar and Delt‐E completely blocked the incidence ofVFin phase 1b. Delt‐E also decreased premature ventricular contractions by 50%, and the incidence of ventricular tachycardia decreased over twofold in phase 1b of ischemia. There was no enhanced tolerance by any of the delta‐2 opioids to the arrhythmogenic effect of reperfusion after long‐term ischemia. In Experiment 2, after 10 minutes of ischemia and 10 minutes of reperfusion, Delt‐II(0.12 mg/kg) reduced the incidence of premature ventricular contractions and ventricular tachycardia compared to controls, and completely blocked the incidence ofVFfollowing 10 minutes of reperfusion. Delt‐Dvar and Delt‐E were without effect, as wasDPDPEfollowing 10 minutes of reperfusion. The antiarrhythmic effect of Delt‐IIduring 10 minutes of ischemia and 10 minutes of reperfusion was completely blocked by the peripherally acting opioid receptor inhibitor naloxone methiodide and the selective delta‐2 opioid receptor inhibitor naltriben mesylate, but not by the selective delta‐1 inhibitor 7‐benzylidene naltrexone maleate. The antagonists alone had no effect on arrhythmogenesis.Conclusions: Peripheral delta‐2 opioid receptor activation by Delt‐II, Delt‐Dvar, and Delt‐E enhanced cardiac tolerance to the arrhythmogenic effects of ischemia.
- 1 July 2013
- Published by Wolters Kluwer Health in International Journal of Gynecological Pathology
- Vol. 32 (4) , 399-405
Recurrent Pregnancy Loss in a Woman With NLRP7 Mutation
Recurrent hydatidiform moles is an uncommon occurrence. Over the past decade, genetic studies of women with multiple recurrent molar pregnancies have revealed that maternal mutations in two different genes, NLRP7 and C6orf221, result in recurrent moles. We report a 23 year old woman, born of unrelated parents, who has experienced three molar pregnancies in succession. Whilst the first pregnancy was classified as a complete hydatidiform mole, the second and third moles defied classification as complete or partial mole using conventional histology, p57 nuclear staining pattern and ploidy studies. Molecular and cytogenetic studies proved that all three molar pregnancies were diploid and biparental in origin. Gene sequencing analysis showed that the patient is homozygous for a previously described mutation in NLRP7. A SNP microarray ruled out the presence of deletion of the NLRP7 locus. This case draws attention to the fact that recurrent molar pregnancies may be the result of specific, identifiable gene mutations, even in patients from non-consanguineous backgrounds. When pathologists encounter patients with molar pregnancies that are diploid and p57 negative and yet have fetal elements such as nucleated red blood cells or immature fetal tissues, it should heighten their suspicion of a possible genetic basis and appropriate molecular genetic workup performed with counseling offered.
- 1 July 2013
- Published by Wolters Kluwer Health in International Journal of Gynecological Pathology
- Vol. 32 (4) , 399-405
Recurrent Pregnancy Loss in a Woman With NLRP7 Mutation
Recurrent hydatidiform moles is an uncommon occurrence. Over the past decade, genetic studies of women with multiple recurrent molar pregnancies have revealed that maternal mutations in two different genes, NLRP7 and C6orf221, result in recurrent moles. We report a 23 year old woman, born of unrelated parents, who has experienced three molar pregnancies in succession. Whilst the first pregnancy was classified as a complete hydatidiform mole, the second and third moles defied classification as complete or partial mole using conventional histology, p57 nuclear staining pattern and ploidy studies. Molecular and cytogenetic studies proved that all three molar pregnancies were diploid and biparental in origin. Gene sequencing analysis showed that the patient is homozygous for a previously described mutation in NLRP7. A SNP microarray ruled out the presence of deletion of the NLRP7 locus. This case draws attention to the fact that recurrent molar pregnancies may be the result of specific, identifiable gene mutations, even in patients from non-consanguineous backgrounds. When pathologists encounter patients with molar pregnancies that are diploid and p57 negative and yet have fetal elements such as nucleated red blood cells or immature fetal tissues, it should heighten their suspicion of a possible genetic basis and appropriate molecular genetic workup performed with counseling offered.
- Open Access
- 11 April 2011
- Published by Wiley in Prenatal Diagnosis
- Vol. 31 (8) , 755-759
Using FISH to increase the yield and accuracy of karyotypes from spontaneous abortion specimens
Objective: Cytogenetic analysis of spontaneous abortions is frequently complicated by culture failure and maternal cell contamination (MCC). The objective of the study is to demonstrate that multiplex fluorescence in situ hybridization (FISH) can increase the yield and accuracy of karyotypes from spontaneous abortion specimens.Method: A multiplex interphase FISH probe set was used to analyze two sample sets. (1) Uncultured tissues from 153 abortions samples with a normal 46,XX karyotype and (2) a series of 171 samples that either failed to grow or were contaminated. MCC studies were performed on 70 cultures where both karyotype and FISH indicated a normal female karyotype.Results: FISH showed 31% (53/171) of the specimens karyotyped as 46,XX were either male or abnormal; 23% (40/118) of these specimens were found to have an abnormal chromosome complement. In specimens with culture failure, FISH showed an abnormal complement in 44.4% (68/153). MCC studies showed 41.49% (29/70) cultures of maternal origin, 45.7% (32/70) fetal, 11.4% (8/70) a maternal/fetal mixture and 1 diploid mole.Conclusion: Results demonstrate the utility of a simple FISH panel in increasing the detection rate of abnormal karyotypes. They also reveal the high frequency of overgrowth of maternal cells in cultured specimens from villi after embryonic loss. Copyright © 2011 John Wiley & Sons, Ltd.
- 11 April 2011
- Published by Wiley in Prenatal Diagnosis
- Vol. 31 (8) , 755-759
Open AccessUsing FISH to increase the yield and accuracy of karyotypes from spontaneous abortion specimens
Objective: Cytogenetic analysis of spontaneous abortions is frequently complicated by culture failure and maternal cell contamination (MCC). The objective of the study is to demonstrate that multiplex fluorescence in situ hybridization (FISH) can increase the yield and accuracy of karyotypes from spontaneous abortion specimens.Method: A multiplex interphase FISH probe set was used to analyze two sample sets. (1) Uncultured tissues from 153 abortions samples with a normal 46,XX karyotype and (2) a series of 171 samples that either failed to grow or were contaminated. MCC studies were performed on 70 cultures where both karyotype and FISH indicated a normal female karyotype.Results: FISH showed 31% (53/171) of the specimens karyotyped as 46,XX were either male or abnormal; 23% (40/118) of these specimens were found to have an abnormal chromosome complement. In specimens with culture failure, FISH showed an abnormal complement in 44.4% (68/153). MCC studies showed 41.49% (29/70) cultures of maternal origin, 45.7% (32/70) fetal, 11.4% (8/70) a maternal/fetal mixture and 1 diploid mole.Conclusion: Results demonstrate the utility of a simple FISH panel in increasing the detection rate of abnormal karyotypes. They also reveal the high frequency of overgrowth of maternal cells in cultured specimens from villi after embryonic loss. Copyright © 2011 John Wiley & Sons, Ltd.